Table 5.
Summary of registries reporting long-term risk of cardiac outcomes in childhood cancer survivors treated with chemotherapy or radiotherapy
| Registry (n-value) | Patient population at assessment, median (range) | Frequency of cardiac events |
|---|---|---|
| CCSS4 (n = 10 724) | 5-year survivors | Cumulative incidence at age 45 years |
| Age 33.7years (11–59) | CAD (grade ≥ 3): 5.3% (95% CI 4.4–6.1) | |
| Follow-up 25.6 years (7.4–39.3) | HF (grade ≥ 3): 4.8% (95% CI 4.1–5.6) | |
| SJLIFE135 (n = 1807) | 10-year survivors | Prevalence |
| Age 31 years (18–65) | LVEF <50%: 5.8% | |
| Follow-up 23 years (10–48) | Systolic dysfunction detected by GLS: 31.8% | |
| BCCSS136 (n = 34 489) | 5-year survivors | Standardized mortality ratios |
| Age, mean 29.6 (5.5–85.6) | Overall cardiac mortality: 3.4 (95% CI 2.9–3.9) | |
| Follow-up, mean 18.0 (0.0–68.7) | Ischaemic heart disease: 2.5 (95% CI 2.0–3.1) | |
| Cardiomyopathy/HF: 5.9 (95% CI 4.4–7.7) | ||
| PanCareSurFup137 (n = 39 152) | 5-year survivors | Prevalence |
| Follow-up 20 years (12–28) | ≥1 cardiac eventa: 2.6% | |
| DCOG-LATER138 (n = 5845) | 5-year survivors | Cumulative 40 years risk |
| Age 27.3 years (5.1 −65.2) | HF (grade ≥ 3): 4.4% (95% CI 3.4–5.5) | |
| Follow-up 19.9 years (5.0–50.4) |
BCCSS, British Childhood Cancer Survivor Study; CAD, coronary heart disease; CCSS, Childhood Cancer Survivor Study; CI, confidence interval; DCOG-LATER, Dutch Childhood Oncology Group–Long-Term Effects After Childhood Cancer; GLS, global longitudinal strain; HF, heart failure; LVEF, left ventricular ejection fraction; PanCareSurFup, pan-European PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies; SJLIFE, St Jude Lifetime Cohort Study.
a
Predominantly symptomatic HF, cardiac ischaemia, pericarditis, valvular disease, or arrhythmia.